NLNK plunges on poor Phase 3 data + updates from reporting companies AEZS ANTH ARDX CHRS CUR EPZM FATE FGEN FOMX HALO IDRA INO KITE KPTI LBIO OPK OTIC PFNX PLX PRTO RARE RNN TBPH TBRA TNXP VTL CMRX RVNC LJPC MSTX

May 10, 2016 No Comments

Updates to the Company Pipeline Database for May 9, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AEZS 3.48 Macimorelin Acetate – Macrilen Adult Growth Deficiency Phase 3 CRL Nov 5 2014. Initiated Phase 3 trial in November 2015, to be completed 3Q 2016 AEZS 3.48 Zoptrex Cancer – […]

Read more

KMPH crashes by over half following Advisory Committee meeting + 60 updates from reporting companies

May 06, 2016 No Comments

Updates to the Company Pipeline Database for May 5, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AERI 14.52 Roclatan – Mercury trials Glaucoma Phase 3 Phase 3 Mercury 1 data due 3Q 2016. Mercury 2 trial data due 2Q 2017 AGIO 43.15 AG-348 Pyruvate kinase deficiency Phase 2 […]

Read more

ORMP Phase 2b diabetes data due in around two weeks + updates from reporting companies ARQL ESPR EXEL INFI LOXO MGNX NVAX ONCE OPHT VNDA XOMA

May 05, 2016 No Comments

Updates to the Company Pipeline Database for May 4, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ORMP 9.50 ORMD-0801 Type 2 Diabetes Phase 2 Phase 2 top-line data due around May 18 2016 – noted on May 4 that data will be released in around 2 weeks ESPR […]

Read more

Pipeline updates with upcoming data from ACHN ARRY EVOK RIGL PRTA NERV. FOLD FDA meeting mid year + updates for NERV LXRX NKTR FOMX

May 04, 2016 No Comments

Updates to the Company Pipeline Database for May 3, 2016, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ACHN 8.25 Odalasvir (ACH-3102), simeprevir and ALS-335 Hepatitis C viral infection (HCV) Phase 2a Phase 2a top-line data due 3Q 2016 ACHN 8.25 Odalasvir (ACH-3102) and sofosbuvir Hepatitis C viral infection […]

Read more

FLML FDA Approval + updates for ADRO ALNY ARGS CEMP CERU GNVC MACK MCRB MRNS NWBO PRTK RGLS TBRA TNXP TRVN XNCR

May 03, 2016 No Comments

Updates to the Company Pipeline Database for May 2, 2016, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ADRO 13.27 CRS-207 and GVAX Pancreas – ECLIPSE trial Pancreatic cancer Phase 2b Phase 2b top-line data to be released 2Q 2016 ADRO 13.27 CRS-207 and GVAX Pancreas and nivolumab – […]

Read more

FDA Approval for ACAD and NUPLAZID. NLNK Phase 3 data due this quarter + IMGN trial design change.

Apr 30, 2016 No Comments

Updates to the Company Pipeline Database for April 29, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ACAD 32.30 Pimavanserin Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016 IMGN 6.85 Mirvetuximab soravtansine – FORWARD I and FORWARD II Cancer – ovarian cancer and relapsed endometrial cancer Phase 3 […]

Read more

Pipeline updates for ACOR ALDR CYTK KERX SGEN

Apr 29, 2016 No Comments

Updates to the Company Pipeline Database for April 28, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ACOR 27.34 Dalfampridine Post stroke deficits Phase 2b/3 Phase 3 data due 4Q 2016 ALDR 27.58 ALD403 – PROMISE 1 Frequent episodic migraine Phase 3 Phase 3 topline data due 1H 2017. […]

Read more

DVAX PDUFA delayed till December 15. OPK PDUFA set for October 22 + THERF CLDX CYTX OASM OCUL VRTX updates

Apr 28, 2016 No Comments

Updates to the Company Pipeline Database for April 27, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary CLDX 4.08 Glembatumumab vedotin Cancer – Squamous cell lung cancer Phase 1/2 Phase 1/2 commenced April 2016 CYTX 0.35 ECCS-50 Scleroderma Phase 3 Pivotal trial initiated August 2015. Noted late April 2016 […]

Read more

FDA requests further trials from CPRX. COLL FDA Approval + SMMT NVIV updates

Apr 26, 2016 No Comments

Updates to the Company Pipeline Database for April 26, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary COLL 18.43 Xtampza ER (oxycodone) Severe pain Approved Approved April 26 2016 CPRX 0.63 Firdapse Lambert-Easton Myasthenic Syndrome (LEMS) RTF – Refusal to file Refusal to file letter reported on Feb 17 […]

Read more